Genelux

Genelux EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of Genelux (GNLX) as of Oct 18, 2026 is -4.11. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was -4.13 — a change of -0.55% (higher).

EV/OCF

-4.11

YoY

-0.55%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of Genelux is 2025 -4.11 . EV/OCF (Enterprise Value to Operating Cash Flow) of Genelux was 2024 -4.13 . It decreases by -0.55% higher compared to the previous year.

The Genelux EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2019
-18.59 USD
Jan 1, 2020
-18.24 USD
Jan 1, 2021
-20.89 USD
Jan 1, 2022
-39.95 USD
Jan 1, 2023
-4.74 USD
Jan 1, 2024
-4.13 USD
Jan 1, 2025
-4.11 USD
The Genelux EV/OCF history
YEAREV/OCFYoY
-4.11-0.55%
-4.13-12.80%
-4.74-88.14%
-39.95+91.29%
-20.89+14.50%
-18.24-1.87%
-18.59—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genelux Stock analysis

What does Genelux do? Genelux Corp, trading under the ticker GNLX, is a biotechnology company based in Westlake Village, California, operating within the Health Care sector. The company has 25 employees and completed its initial public offering on January 26, 2023. Genelux focuses on developing oncolytic viral immunotherapies for solid tumor cancers. Its lead product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a modified vaccinia virus (VACV), a stable DNA virus with significant engineering potential. The company is currently advancing Olvi-Vec through Phase II clinical trials for platinum-resistant or refractory ovarian cancer (PRROC). Additionally, Genelux is developing a platform called Virus and Vaccine (Neoantigen)-Enhanced Adoptive Cell Therapy (V2ACT), which aims to enhance cancer neoantigen-specific T cell activity within tumors. The company also has an animal health product candidate, V-VET1, a genetically characterized, veterinary-grade oncolytic vaccinia virus that is a naturally attenuated isolate. Genelux's website is https://genelux.com/ and it is registered with the ISIN US36870H1032. The company's operations and product development are centered on innovative viral-based therapies for both human and animal health applications. Genelux is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genelux stock

EV/OCF (Enterprise Value to Operating Cash Flow) of Genelux is -4.11 in 2025.

EV/OCF (Enterprise Value to Operating Cash Flow) of Genelux changed from -4.13 to -4.11, representing a -0.55% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) Genelux since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s Genelux with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Genelux

All Key Metrics — Genelux